Lebrikizumab

EBGLYSS

Open Lebrikizumab in the interactive console ↗

What it isMonoclonal antibody selectively neutralizing IL-13; moderate-to-severe atopic dermatitis.

Why this oneUnlike tralokinumab, it preserves IL-13 binding to its decoy receptor while blocking pathogenic signaling.

What limits itConjunctivitis and keratitis can end treatment; address helminth infection first and avoid live vaccines.

FDA-approved for

Moderate-to-severe atopic dermatitis (2024)

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Moderate-to-severe atopic dermatitis (inadequately controlled with topical Rx or when not advisable)	Adults and pediatric 12 yr and older weighing >=40 kg	500 mg (two 250 mg injections) SC at Week 0 and Week 2	250 mg SC every 2 weeks until Week 16 or later, then 250 mg every 4 or every 8 weeks (maintenance)

Renal No clinically significant differences in mild or moderate renal impairment (no dedicated study)

Hepatic Undefined (not studied; not expected to undergo significant hepatic elimination)

Instructions

Administer by subcutaneous injection (abdomen, thigh, or back of upper arm)
Complete all age-appropriate vaccinations before starting; avoid live vaccines during treatment
May be used with or without topical corticosteroids

Contraindications

Prior serious hypersensitivity to lebrikizumab-lbkz or any excipients in EBGLYSS

Cautions

Hypersensitivity reactions including angioedema and urticaria
Conjunctivitis and keratitis
Parasitic (helminth) infections - treat pre-existing infection before starting
Avoid live vaccines during treatment

Adverse reactions

Conjunctivitis
Injection site reactions
Herpes zoster

Pregnancy Insufficient human data; monoclonal antibodies are actively transported across the placenta. No adverse embryo-fetal effects in monkeys.

Lactation No data on presence in human milk; endogenous IgG and monoclonal antibodies are present in human milk.

NO BOXED WARNINGS

Principal riskConjunctivitis